| Entry |
|
|---|
| Name |
Glecaprevir and pibrentasvir;
Mavyret (TN) |
|---|
| Product |
|
|---|
| Component |
|
|---|
| Remark |
| Therapeutic category: | 6250 |
|
|---|
| Efficacy |
Antiviral |
|---|
| Disease |
Chronic hepatitis C virus infection [DS: H00413] |
|---|
| Comment |
Glecaprevir is an inhibitor and a substrate of P-gp, BCRP, OATP1B1/1B3.
Pibrentasvir is a substrate of P-gp; it is also an inhibitor of P-gp, BCRP and OATP1B1.
|
|---|
| Target |
|
|---|
| Metabolism |
|
|---|
| Interaction |
Transporter inhibition: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429], SLCO1B1 [HSA: 10599], SLCO1B3 [HSA: 28234]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP57 Glecaprevir and pibrentasvir
D11014 Glecaprevir and pibrentasvir <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Glecaprevir/ Pibrentasvir
D11014 Glecaprevir and pibrentasvir
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D11014 Glecaprevir and pibrentasvir
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11014
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11014
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11014
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11014
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D11014
|
|---|
| Other DBs |
|
|---|
